Andrew Conrad, Ph.D., Chief Scientific Officer of Laboratory Corporation of America (LabCorp), Executive Director of Oncology and Pathology for DIANON/US LABS, and Executive Head of Clinical Trials Services for Esoterix Clinical Trials, Inc.
He is also the Co-Founder and Chief Scientific Officer of LabCorp's National Genetics Institute.
National Genetics Institute
(NGI) performs over three million PCR reactions per year and is one of the largest genetics laboratories in the world.
The primary focus of Dr. Conrad's
research has been on the effects and manifestations of chronic viral illnesses as measured by the polymerase chain reaction (PCR).
He also conducts research on the role of gene expression in cancer and is the Responsible Head for the FDA Product License for The UltraQual Assay, a Nucleic Acid Test (NAT) for the detection of HIV-1, and HCV in plasma from large numbers of donors.
has more than eighty-five publications in scientific and medical journals.
Dr. Conrad also serves as the Chief Scientific Officer of North Carolina Research Campus (NCRC) in Kannapolis, North Carolina.
He is a member of the Board of Directors for Dole and Castle & Cooke.
Dr. Conrad founded the California Health and Longevity Institute (CHLI) where he serves as the Laboratory Director.
operates preventive and early detection medical facilities at the new world-class wellness centers being built around the United States in partnership with Dole, Wellpoint Inc.
and the Four Seasons Hotels.
Dr. Conrad graduated with a B.S. in Neurobiology and a Ph.D. in Cell Biology from the University of California Los Angeles.